Oracle Alpha’s Avidity Biosciences RNAM Stock Holding History

Oracle Alpha’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$268K	Sell	10,518 -2,478	-19%	-$38.8K	0.48%	96
2023 Q4	$118K	Buy	+12,996	New	+$86.9K	0.15%	229

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Oracle Alpha's RNAM Position: Q1 2024 in Review

Oracle Alpha reduced its Avidity Biosciences (RNAM) stake by 19% in Q1 2024, selling an estimated $38.8K and leaving 10,518 shares worth $268K. The position accounts for 0.48% of the portfolio, ranked #96.

Oracle Alpha first reported a position in RNAM in Q4 2023 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold RNAM as of Q1 2024.

Oracle Alpha held 10,518 shares of Avidity Biosciences worth $268K as of Q1 2024.
Oracle Alpha sold 2,478 Avidity Biosciences shares in Q1 2024, an estimated $38.8K.
Avidity Biosciences made up 0.48% of Oracle Alpha's portfolio in Q1 2024, its #96 holding.
Oracle Alpha first reported a position in Avidity Biosciences in Q4 2023 and has held it in 2 quarters since.
158 funds tracked by Wall St. Rank held Avidity Biosciences as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.